^
    Back
    Association details:
    Biomarker:HER-2 positive
    Cancer:Esophageal Adenocarcinoma
    Drug:Opdivo (nivolumab) (PD1 inhibitor) +
    Herceptin (trastuzumab) (HER2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    JAMA Oncol
    Title:

    Efficacy of Ipilimumab vs FOLFOX in Combination With Nivolumab and Trastuzumab in Patients With Previously Untreated ERBB2-Positive Esophagogastric Adenocarcinoma: The AIO INTEGA Randomized Clinical Trial

    Published date:
    08/01/2022
    Excerpt:
    Central post hoc biomarker analysis (84 patients) showed PD-1 ligand 1 (PD-L1) combined positive score of 1 or greater in 59 patients (72%) and 5 or greater in 46 patients (56%) and confirmed ERBB2 positivity in 76 patients. The observed overall survival rate at 12 months was 70% (95% CI, 54%-81%) with FOLFOX and 57% (95% CI, 41%-71%) with ipilimumab...In this randomized clinical trial, trastuzumab, nivolumab, and FOLFOX showed favorable efficacy compared with historical data and trastuzumab, nivolumab, and ipilimumab in ERBB2-positive EGA.
    Secondary therapy:
    FOLFOX
    DOI:
    10.1001/jamaoncol.2022.2228
    Trial ID:
    INTEGA
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO 2021
    Title:

    LBA54 - Ipilimumab or FOLFOX in combination with nivolumab and trastuzumab in previously untreated HER2 positive locally advanced or metastastic esophagogastric adenocarcinoma (EGA): Results of the randomized phase II INTEGA trial (AIO STO 0217)

    Published date:
    09/13/2021
    Excerpt:
    The INTEGA trial compared different immunotherapy regimens in 1st line HER2+ EGA....The 1° endpoint of 70% OSR@12 was reached in arm B, but not in arm A (57%)...Trast/nivo/FOLFOX showed increased efficacy compared to the ToGA regimen, whereas trast/nivo/ipi did not improve OS over trast/chemo.
    Secondary therapy:
    FOLFOX
    Trial ID:
    INTEGA